The markets opened lower with the Dow losing 27 points to 16,778 as twenty-four European banks failed their stress test. Nasdaq fell 15 points to 4,467.

On the upside

NQ Mobile (NYSE: NQ) filed its annual report for 2013 and regained full compliance with the Securities and Exchange Commission.

Novavax (Nasdaq: NVAX) will begin a Phase 1 Ebola vaccine clinical trial in December.

Aeterna Zentaris (Nasdaq: AEZS) assigned a full-time sales force to begin selling ASCEND Therapeutics' estrogen replacement therapy EstroGel beginning November 17.

On the downside

The defeat of pro-business Brazilian presidential candidate Aecio Neves sent shares of Petrobras (NYSE: PBR) tumbling.

The Food and Drug Administration requested additional data from Sarepta Therapeutics (Nasdaq: SRPT) for its New Drug Application to treat Duchenne muscular dystrophy with eteplirsen.

Pfizer (NYSE: PFE) ended its development agreement with Pain Therapeutics (Nasdaq: PTIE) for the pain treatment Remoxy.

In the broad market, declining issues outpaced advancers by a margin of more than 4 to 1 on the NYSE and by a nearly 7 to 2 on Nasdaq. The broader S&P 500 lost 7 points to 1957. Bitcoin eased a fraction to $352.